DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies

Acta Neuropathologica

Volumn 125, Issue 3, 2013, Pages 359-371

  Schwalbe, Edward C ^a   Williamson, Daniel ^a   Lindsey, Janet C ^a   Hamilton, Dolores ^a   Ryan, Sarra L ^a   Megahed, Hisham ^a   Garami, Miklós ^b   Hauser, Peter ^b   Dembowska Baginska, Bozena ^c   Perek, Danuta ^c   Northcott, Paul A ^d   Taylor, Michael D ^d   Taylor, Roger E ^e   Ellison, David W ^f   Bailey, Simon ^a   Clifford, Steven C ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e SINGLETON HOSPITAL   (United Kingdom)

^f ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Biomarkers; Medulloblastoma; Methylation; Prognosis; Subgroups

Indexed keywords

BIOLOGICAL MARKER; FORMALDEHYDE; INTERLEUKIN 8; MESSENGER RNA; PARAFFIN; PROTEIN G3; PROTEIN G4; PROTEIN MX11; SONIC HEDGEHOG PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; WNT PROTEIN;

ADOLESCENT; ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CHILD; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; MOLECULAR MODEL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RNA METHYLATION; SCHOOL CHILD; SHH GENE; TRANSCRIPTOMICS; TUMOR BIOPSY; TUMOR CLASSIFICATION; TUMOR GENE; VALIDATION PROCESS; WNT GENE;

ADOLESCENT; ADULT; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BIOPSY; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 17; COHORT STUDIES; COMPUTATIONAL BIOLOGY; DNA FINGERPRINTING; DNA METHYLATION; FEMALE; FORMALDEHYDE; FROZEN SECTIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEDGEHOG PROTEINS; HUMANS; INFANT; INTERLEUKIN-8; MALE; MEDULLOBLASTOMA; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS C-MYC; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84878874877     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-012-1077-2     Document Type: Article

References (53)

1. Anderton JA, Lindsey JC, Lusher ME, Gilbertson RJ, Bailey S, Ellison DW, Clifford SC (2008) Global analysis of the medulloblastoma epigenome identifies disease-subgroup-specific inactivation of COL1A2. Neuro Oncol 10:981-994
2. Bibikova M, Lin Z, Zhou L, Chudin E, Garcia EW, Wu B, et al. (2006) High-throughput DNA methylation profiling using universal bead arrays. Genome Res 16:383-393
3. Brunet J-P, Tamayo P, Golub TR, Mesirov JP (2004) Metagenes and molecular pattern discovery using matrix factorization. Proc Natl Acad Sci USA 101:4164-4169
4. Cairns JM, Dunning MJ, Ritchie ME, Russell R, Lynch AG (2008) BASH: a tool for managing BeadArray spatial artefacts. Bioinformatics 24:2921-2922
5. Cascon A, Robledo M (2012) MAX and MYC: a heritable breakup. Cancer Res 72:3119-3124
6. Chang CH, Housepian EM, Herbert C Jr (1969) An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology 93:1351-1359
7. Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, et al. (2011) Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 29:1424-1430
8. Clifford SC, Lusher ME, Lindsey JC, Langdon JA, Gilbertson RJ, Straughton D, Ellison DW (2006) Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle 5:2666-2670
9. Curran EK, Sainani KL, Le GM, Propp JM, Fisher PG (2008) Gender affects survival for medulloblastoma only in older children and adults: a study from the surveillance epidemiology and end results registry. Pediatr Blood Cancer 52:60-64
10. Diede SJ, Guenthoer J, Geng LN, Mahoney SE, Marotta M, Olson JM, Tanaka H, Tapscott SJ (2010) DNA methylation of developmental genes in pediatric medulloblastomas identified by denaturation analysis of methylation differences. Proc Natl Acad Sci USA 107:234-239
11. Duan KB, Rajapakse JC, Wang H, Azuaje F (2005) Multiple SVM-RFE for gene selection in cancer classification with expression data. IEEE Trans Nanobioscience 4:228-234
12. Dunning MJ, Smith ML, Ritchie ME, Tavare S (2007) beadarray: R classes and methods for Illumina bead-based data. Bioinformatics 23:2183-2184
13. Ellison DW, Dalton J, Kocak M, Nicholson SL, Fraga C, Neale G, Kenney AM, Brat DJ, Perry A, Yong WH, Taylor RE, Bailey S, Clifford SC, Gilbertson RJ (2011) Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol 121:381-396
14. Ellison DW, Kocak M, Dalton J, Megahed H, Lusher ME, Ryan SL, Zhao W, Nicholson SL, Taylor RE, Bailey S, Clifford SC (2011) Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol 29:1400-1407
15. Ellison DW, Onilude OE, Lindsey JC, Lusher ME, Weston CL, Taylor RE, Pearson AD, Clifford SC (2005) beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol 23:7951-7957
16. Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, et al. (2006) Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 7:813-820
17. Heagerty PJ, Lumley T, Pepe MS (2000) Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56:337-344
18. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003
19. Jones DT, Jager N, Kool M, Zichner T, Hutter B, Sultan M, et al. (2012) Dissecting the genomic complexity underlying medulloblastoma. Nature 488:100-105
20. Kongkham PN, Northcott PA, Croul SE, Smith CA, Taylor MD, Rutka JT (2010) The SFRP family of WNT inhibitors function as novel tumor suppressor genes epigenetically silenced in medulloblastoma. Oncogene 29:3017-3024
21. Kool M, Korshunov A, Remke M, Jones DT, Schlanstein M, Northcott PA, et al. (2012) Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol 123:473-484
22. Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, van Sluis P, et al. (2008) Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS ONE 3:e3088
23. Lamont JM, McManamy CS, Pearson AD, Clifford SC, Ellison DW (2004) Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res 10:5482-5493
24. Langdon JA, Lamont JM, Scott DK, Dyer S, Prebble E, Bown N, Grundy RG, Ellison DW, Clifford SC (2006) Combined genome-wide allelotyping and copy number analysis identify frequent genetic losses without copy number reduction in medulloblastoma. Genes Chromosomes Cancer 45:47-60
25. Lindsey JC, Anderton JA, Lusher ME, Clifford SC (2005) Epigenetic events in medulloblastoma development. Neurosurg Focus 19:E10
26. Lindsey JC, Lusher ME, Anderton JA, Bailey S, Gilbertson RJ, Pearson AD, Ellison DW, Clifford SC (2004) Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling. Carcinogenesis 25:661-668
27. Lindsey JC, Lusher ME, Anderton JA, Gilbertson RJ, Ellison DW, Clifford SC (2007) Epigenetic deregulation of multiple S100 gene family members by differential hypomethylation and hypermethylation events in medulloblastoma. Br J Cancer 97:267-274
28. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-109
29. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23:9067-9072
30. Missiaglia E, Williamson D, Chisholm J, Wirapati P, Pierron G, Petel F, Concordet JP, Thway K, Oberlin O, Pritchard-Jones K, Delattre O, Delorenzi M, Shipley J (2012) PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol 30:1670-1677
31. Ning Y, Manegold PC, Hong YK, Zhang W, Pohl A, Lurje G, Winder T, Yang D, LaBonte MJ, Wilson PM, Ladner RD, Lenz HJ (2011) Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. Int J Cancer 128:2038-2049
32. Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, Bouffet E, Clifford SC, Hawkins CE, French P, Rutka JT, Pfister S, Taylor MD (2011) Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 29:1408-1414
33. Northcott PA, Shih DJ, Remke M, Cho YJ, Kool M, Hawkins C, et al. (2012) Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathol 123:615-626
34. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al. (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17:510-522
35. Parsons DW, Li M, Zhang X, Jones S, Leary RJ, Lin JC, et al. (2011) The genetic landscape of the childhood cancer medulloblastoma. Science 331:435-439
36. Pfister SM, Remke M, Benner A, Mendrzyk F, Toedt G, Felsberg J, et al. (2009) Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol 27:1627-1636
37. Pizer BL, Clifford SC (2009) The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials. Br J Neurosurg 23:364-375
38. Pugh TJ, Weeraratne SD, Archer TC, Pomeranz Krummel DA, Auclair D, Bochicchio J, et al. (2012) Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 488:106-110
39. R Development Core Team (2011) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna
40. Robinson G, Parker M, Kranenburg TA, Lu C, Chen X, Ding L, et al. (2012) Novel mutations target distinct subgroups of medulloblastoma. Nature 488:43-48
41. Rousseeuw PJ (1987) Silhouettes: a graphical aid to the interpretation and validation of cluster analysis. J Comput Appl Math 20:53-65
42. Rutkowski S, von Bueren A, von Hoff K, Hartmann W, Shalaby T, Deinlein F, et al. (2007) Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91. Clin Cancer Res 13:2651-2657
43. Ryan SL, Schwalbe EC, Cole M, Lu Y, Lusher ME, Megahed H, et al. (2012) MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathol 123:501-513
44. Schwalbe EC, Lindsey JC, Straughton D, Hogg TL, Cole M, Megahed H, Ryan SL, Lusher ME, Taylor MD, Gilbertson RJ, Ellison DW, Bailey S, Clifford SC (2011) Rapid diagnosis of medulloblastoma molecular subgroups. Clin Cancer Res 17:1883-1894
45. Scott DK, Straughton D, Cole M, Bailey S, Ellison DW, Clifford SC (2006) Identification and analysis of tumor suppressor loci at chromosome 10q23.3-10q25.3 in medulloblastoma. Cell Cycle 5:2381-2389
46. Simon RM, Subramanian J, Li MC, Menezes S (2011) Using cross-validation to evaluate predictive accuracy of survival risk classifiers based on high-dimensional data. Brief Bioinform 12:203-214
47. Tamayo P, Scanfeld D, Ebert BL, Gillette MA, Roberts CWM, Mesirov JP (2007) Metagene projection for cross-platform, cross-species characterization of global transcriptional states. Proc Natl Acad Sci USA 104:5959-5964
48. Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, et al. (2012) Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 123:465-472
49. Taylor RE, Bailey CC, Robinson K, Weston CL, Ellison D, Ironside J, Lucraft H, Gilbertson R, Tait DM, Walker DA, Pizer BL, Imeson J, Lashford LS (2003) Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of paediatric oncology/United Kingdom Children;s Cancer Study Group PNET-3 Study. J Clin Oncol 21:1581-1591
50. Taylor RE, Bailey CC, Robinson KJ, Weston CL, Walker DA, Ellison D, Ironside J, Pizer BL, Lashford LS (2005) Outcome for patients with metastatic (M2-3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy. Eur J Cancer 41:727-734
51. Thompson MC, Fuller C, Hogg TL, Dalton J, Finkelstein D, Lau CC, Chintagumpala M, Adesina A, Ashley DM, Kellie SJ, Taylor MD, Curran T, Gajjar A, Gilbertson RJ (2006) Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 24:1924-1931
52. Wang J, Wen S, Symmans WF, Pusztai L, Coombes KR (2009) The bimodality index: a criterion for discovering and ranking bimodal signatures from cancer gene expression profiling data. Cancer Inform 7:199-216
53. Zervos AS, Gyuris J, Brent R (1993) Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites. Cell 72:223-232